Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIBF 1120 (nintedanib) + docetaxel vs placebo + docetaxel in second-line NSCLC
CTR20132634Phase 3Active
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of nintedanib in non-small cell lung cancer (NSCLC), sponsored by Boehringer Ingelheim. Started Nov 2014; status: active.
02
Drugs
nintedanib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20132634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20132634.